Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to ...

Vascular Endothelial Growth Factor Inhibitor market grows 4.0% CAGR as biosimilars and personalized medicine expand ...

Chief Executive Officer Craig Parker used a discussion at a 2026 investor summit to outline the company’s focus on Wnt pathway biology and antibody engineering, with an emphasis on retinal vascular ...

A newly identified driver of melanoma growth not only promotes tumor blood supply but also helps tumors evade immune attack.

Cabozantinib plus temozolomide led to favorable short-term progression-free survival in a single-arm trial of patients with advanced leiomyosarcoma. The combination of cabozantinib with temozolomide ...

Ocular Therapeutix's current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA holding a 63% global market share in 2024. Read why OCUL stock is a sell.

Researchers at NYU Langone Health and its Perlmutter Cancer Center have discovered that a gene-regulating molecule called ...

Eylea was under pressure in 2025. Sales of Eylea plunged 42% in the United States to $2.7 billion, impacted by lower sales ...

A molecule that helps regulate gene activity has also been shown to drive skin cancer growth and tumors' ability to evade ...

A molecule that helps regulate gene activity has also been shown to drive skin cancer growth and tumors' ability to evade ...

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.

Arteries can narrow with fatty buildup. Blood struggles to move. Oxygen drops. A heart attack can follow, and it remains the world’s top killer. Researchers at the University of California San Diego ...